The revision of the pharmaceutical legislation - it is time to act for nuclear medicine in Europe

Marianne Patt¹, Clemens Decristoforo², Amélie de Martini³, Michel Koole⁴, Wim J G Oyen^{5

6

7}, Oliver C Kiss⁸

Affiliations

¹ Section Radiopharmacy, Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
³ European Association of Nuclear Medicine, Vienna, Austria.
⁴ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Louvain, Belgium.
⁵ Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy.
⁶ Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
⁷ Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁸ Department of Targetry, Target Chemistry and Radiopharmacy, Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. o.kiss@hzdr.de.

Editorial

Marianne Patt et al. Eur J Nucl Med Mol Imaging. 2023 Dec.

. 2023 Dec;51(1):20-24.

doi: 10.1007/s00259-023-06472-1.

Marianne Patt¹, Clemens Decristoforo², Amélie de Martini³, Michel Koole⁴, Wim J G Oyen^{5

6

7}, Oliver C Kiss⁸

¹ Section Radiopharmacy, Department of Nuclear Medicine, University Hospital Augsburg, Augsburg, Germany.
² Department of Nuclear Medicine, Medical University Innsbruck, Innsbruck, Austria.
³ European Association of Nuclear Medicine, Vienna, Austria.
⁴ Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, KU Leuven, Louvain, Belgium.
⁵ Department of Biomedical Sciences and Humanitas Clinical and Research Centre, Department of Nuclear Medicine, Humanitas University, Milan, Italy.
⁶ Department of Radiology and Nuclear Medicine, Rijnstate Hospital, Arnhem, The Netherlands.
⁷ Department of Medical Imaging, Nuclear Medicine, Radboud University Medical Centre, Nijmegen, The Netherlands.
⁸ Department of Targetry, Target Chemistry and Radiopharmacy, Institute for Radiopharmaceutical Cancer Research, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), Dresden, Germany. o.kiss@hzdr.de.

No abstract available

Conflict of interest statement

The authors declare no competing interests.

1. Deutsch E. Clinical PET: its time has come? J Nucl Med. 1993;34(7):1132–1133. - PubMed
1. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute D, Uprimny C, et al. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J Nucl Med. 2007;48(4):508–518. doi: 10.2967/jnumed.106.035667. - DOI - PubMed
1. Krenning EP, Kwekkeboom DJ, Valkema R, Pauwels S, Kvols LK, De Jong M. Peptide receptor radionuclide therapy. Ann N Y Acad Sci. 2004;1014:234–245. doi: 10.1196/annals.1294.026. - DOI - PubMed
1. Hennrich U, Eder M. [177Lu]Lu-PSMA-617 (PluvictoTM): the first FDA-approved radiotherapeutical for treatment of prostate cancer. Pharmaceuticals (Basel) 2022;15(10):1292. doi: 10.3390/ph15101292. - DOI - PMC - PubMed
1. Council Directive 89/343/EEC of 3 May 1989 extending the scope of Directives 65/65/EEC and 75/319/EEC and laying down additional provisions for radiopharmaceuticals. Official Journal of the European Communities. 1989. http://data.europa.eu/eli/dir/1989/343/oj/eng. Accessed 27 Aug 2023.